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Aims Connexins (Cxs) play a role in the contractility of the aorta wall. We investigated how connexins of the endothelial




We subjected both wild-type (WT) mice and mice lacking Cx40 (Cx402/2), to either a two-kidney, one-clip pro-
cedure or to N-nitro-L-arginine-methyl-ester treatment, which induce renin-dependent and -independent hyperten-
sion, respectively. All hypertensive mice featured a thickened aortic wall, increased levels of Cx37 and Cx45 in SMC,
and of Cx40 in EC (except in Cx402/2 mice). Cx43 was up-regulated, with no effect on its S368 phosphorylation,
only in the SMCs of renin-dependent models of hypertension. Blockade of the renin–angiotensin system of Cx402/2
mice normalized blood pressure and prevented both aortic thickening and Cx alterations. Ex vivo exposure of WT
aortas, carotids, and mesenteric arteries to physiologically relevant levels of angiotensin II (AngII) increased the levels
of Cx43, but not of other Cx. In the aortic SMC line of A7r5 cells, AngII activated kinase-dependent pathways and
induced binding of the nuclear factor-kappa B (NF-kB) to the Cx43 gene promoter, increasing Cx43 expression.
Conclusion In both large and small arteries, hypertension differently regulates Cx expression in SMC and EC layers. Cx43 is selec-
tively increased in renin-dependent hypertension via an AngII activation of the extracellular signal-regulated kinase
and NF-kB pathways.
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1. Introduction
The connexin (Cx) channels of gap junctions provide pathways for the
communication of both endothelial cells (ECs) and smooth muscle cells
(SMCs) along the vascular system,1 in patterns which vary in different
species and vessels.2,3 Gap junctions allow for spreading of signals coor-
dinating both vasoconstriction and vasodilation. ECs predominantly
express Cx37, Cx40, and some Cx43, whereas SMCs are coupled by
Cx43 and Cx45, sometimes with minimal levels of Cx40 and Cx37.1,4
Conditions leading to alterations in the arterial wall and/or associated
with altered mechanical stress of ECs and SMCs induce changes of
several Cx1,5,6 and, conversely, mice lacking Cx40 or Cx43 feature
abnormal regulation of blood pressure.5,7 –11
Chronic hypertension results in hypertrophic remodelling of the
aortic and carotid walls in humans and animals,12–14 as an adaptation
to altered hemodynamic.15 These alterations, which result in
increased isobaric stiffness16 predominantly in the aorta and
proximal elastic arteries15 and in cardiac after-load,17 also modify vas-
cular Cx. However, it is still unclear whether different Cxs similarly
change in various forms of hypertension. We have investigated
these questions by comparing mice lacking Cx40, a genetic, renin-
dependent model of hypertension,7,8,11 with wild-type (WT) mice.
Both types of mice were induced to develop a renin-dependent
or -independent hypertension by clipping one renal artery (two-
kidney, one-clip model; 2K1C)5 and by inhibiting nitric oxide
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synthase (N-nitro-L-arginine methyl ester model; L-NAME),5,7,10,18
respectively.
Our data show that chronic hypertension specifically regulates Cxs
in distinct layers of large and small size arteries, by mechanisms that
vary for different Cxs. Chronic hypertension up-regulates Cx40 in
ECs, and Cx37 and Cx45 in SMCs. In contrast, Cx43 is selectively
up-regulated in the SMCs of the renin-dependent models of hyperten-
sion, by a hitherto unknown mechanism, which we now demonstrate
involves the AngII activation of the ERK and NF-kB pathways.
2. Methods
2.1 Animal experiments
The investigation confirms with the Guide for the Care and Use of Lab-
oratory Animals published by US National Institution of Health (NIH Pub-
lication No. 85-23, revised 1996), mouse care, surgery, and euthanasia
procedures were approved by our institution and the Veterinary Office
(Lausanne, Switzerland), and confirms with the guide for the care and
use of laboratory animals (University of Lausanne, A5552-01). The gener-
ation of Cx402/2 mice and their genotypic characterization have been
described.7,11,19 Breeding pairs were crossed with control C57BL6 part-
ners. Identification of WT and homozygous Cx402/2 mice was per-
formed by PCR of genomic DNA.7,11 Three- to 4-month-old animals,
from litters obtained after at least 10 backcrosses into the C57/BL6 back-
ground, were used in all the experiments. WT and Cx402/2 mice (5–17
mice per group) with a comparable genetic background were compared in
each of the following protocols: (i) for the 2K1C model, the left renal
artery was clipped with a 0.12 mm internal diameter U-shaped silver
clip for 4 weeks;5,7,11 (ii) addition to drinking water of either 3 mg/kg/
day candesartan (Cilexetilw, Astra Zeneca) or 10 mg/kg/day ramipril
(Aventis),7 addition to drinking water of 80 mg/kg/day L-NAME (Sigma),
for 3 weeks.
2.2 Measurement of blood pressure
One day before sacrifice, the right carotid artery was penetrated with a
catheter connected to a pressure transducer and a computerized data
acquisition system,5,7,11,18,20 which recorded heart rate and both diastolic
and systolic intra-arterial pressure in conscious mice, every 20 s. The
system comprised a pressure transducer 156 PC PK 87802 (Honeywell
Micro-Switch, Richardson, TX, USA), an HP9000-300 computer
(Hewlett-Packard, Palo Alto, CA, USA), and a PP3852A scanner (Hewlett-
Packard).21 All data are shown as the mean of the diastolic and systolic
values (MBP). In some experiments, MBP was monitored in 7-day pre-
trained mice by a non-invasive computerized tail cuff method (BP-2000,
Visitech Systems). The system automatically performs a cuff inflation
and deflation cycle and records pulse rate and blood pressure.5,7,11
Records were provided for an average evaluation of blood pressure
over a 10-day period. In awake mice, these measurements correlated
well with those made by the intra-arterial method (data not shown).
2.3 Measurement of plasma renin
Plasma renin activity (PRA) was measured by a microassay based on angio-
tensin I (AngI) trapping by an antibody.5,7 The amounts of AngI produced
during the incubation period were then determined using a sensitive
radioimmunoassay with commercially available 125I-angiotensin I (Anawa
Trading SA).5,7
2.4 Measurement of aorta thickness
Euthanized mice were perfused with PBS through the left ventricle and the
aortas were excised for cryosectioning. The combined thickness (intima
and media) and the internal diameter of the aorta were measured.22
2.5 Ex vivo studies
Fragments of freshly excised aortas, carotids, and superior mesenteric
arteries were opened longitudinally in DMEM and exposed to various
concentrations of angiotensin II (AngII; Calbiochem), in the presence or
absence of either 20 mM candesartan or 20 mM PD98059 (Calbiochem)
for the durations given below.
2.6 Cells
A7r5 cells, a line derived from rat embryonic aorta SMCs,23
were obtained from Urs Ruegg (University of Geneva and Lausanne,
Switzerland)24,25 and cultured in Dulbecco’s medium. The clone we
used in this study expressed the AngII receptor AT1a (see Supplementary
material online, Figure S1).
2.7 Connexin analysis
RNA was analysed by real-time qPCR,5,7,11 using specific primers (see
Supplementary material online, Table S1). For en face immunostaining,
aortas were fixed, opened longitudinally, and labelled for Cx40,
Cx37,2,26 and Cx43, using antibodies AB1726 (Chemicon) and AB1738
(Chemicon), diluted 1:50, respectively. For immunolabelling of sections
and western blots, the freshly excised vessels were processed as
reported.5,27 To prepare enriched ECs or SMCs, aortas were longitudin-
ally opened in 100 mL PBS, pinned on silicone, and ECs were scraped with
a scalpel. The remaining tissue provided enriched SMCs. Samples were
homogenized in SDS lysis buffer and run on a 12.5% gel. Membranes
were incubated overnight with the antibodies listed above, or antibodies
against Cx45 (AB1748, Chemicon), a-tubulin (T5168, Sigma), or b-actin
(A5441, Sigma), p-ERK1/2 and ERK1/2 (9101 and 4695, Cell Signaling).
To detect phosphorylated Cx43, we used antibodies AB3841 (Chemicon)
and sc-22267-r (Santa Cruz), directed against the Ser368 and Ser262
forms, respectively. Immunolabelled proteins were detected by chemilu-
minescence, and Cx signals normalized to either tubulin or b-actin
levels (given that we could not detect tubulin in purified ECs).11
2.8 Mechanism of Cx43 up-regulation
A7r5 cells were transiently transfected using TRANSFAST (Catalys).28
Reporter plasmids consisted of the luciferase gene fused downstream of
699 or 258 bp fragments of the promoter of the rat Gja1 gene, both of
which included a kB-binding site. The following day, cells were incubated
for 4 h in the presence or absence of 2 mM AngII, and extracts were prepared
for dual-luciferase reporter assay (Promega).28 A mutation of the putative
nuclear factor-kappa B (NF-kB)-binding site was generated in the Cx43 pro-
moter by Quick Site-directed mutagenesis (Stratagene, Europe). The PCR
amplification was performed using pGL3-258 and pGL3-699 as templates,
and the following forward and reverse primers: 50-TAGTAGGGC
TTGTTTCAGtatATGACCAGGGGGAGGGAGAAG-30 (NF-kB sequence
underlined and mutagenized nucleotides in lowercase), and 50-CTTC
TCCCTCCCCCTGGTCATATACTGAAACAAGCCCTACTA-30.
A7r5 cells were cross-linked and processed for chromatin immunopre-
cipitation.28,29 Lysates were immunoprecipitated overnight with anti-
bodies against either NF-kB p65 (sc-372 X; Santa Cruz Biotechnology)
or NF-kB p50 (sc-1190 X; Santa Cruz). Complexes were eluted, purified,
and DNA PCR-amplified to give a 246 bp fragment containing the kB site
of the rat Gja1 promoter. For ERK and IkBa western blots, A7r5 cells
were processed as described above. To detect NF-kB, nuclear extracts
were prepared using an NE-PER kit (Pierce). The following antibodies
were used: p-IkBa and IkBa (SC-7977 and SC-203, Santa Cruz), and
p-ERK1/2 and ERK1/2 (9101 and 4695, Cell Signaling).
2.9 Statistical analysis
All western blot and qPCR experiments were quantitatively analysed and
results are shown as mean þ SEM. One-way analysis of variance
(ANOVA) was performed to compare the mean values between
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groups, using the post hoc Bonferroni test, as provided by The Statistical
Package for the Social Science (SPSS 17.0, Chicago, IL, USA).
3. Results
3.1 Mouse characteristics
Compared with WT, Cx402/2 mice featured the changes previously
reported,7,11 including increased blood pressure due to elevated cir-
culating renin (PRA), and a thickening of the aortic media (see Sup-
plementary material online, Table S2). Treatment with candesartan,
an antagonist of the AT1 AngII receptor, or ramipril, an inhibitor of
the AngII-converting enzyme, did not alter the blood pressure or
the aorta thickness of WT mice, in spite of a significant increase in
PRA. Both treatments reduced to control the values of blood
pressure and aorta thickness of Cx402/2 mice, without altering
PRA (see Supplementary material online, Table S2).
The 2K1C treatment increased the blood pressure, PRA, and
aorta thickness of WT mice to the levels observed in Cx402/2
mice, which were not affected by this protocol (see Supplementary
material online, Table S2).The administration of L-NAME increased
blood pressure by 19% and aorta thickness, but not PRA of WT
mice. A smaller (8%) increase in blood pressure was observed in
Cx402/2 mice, whose PRA remained significantly higher than that
in WT littermates (see Supplementary material online, Table S2).
The expression of the AT1a receptor was lower in aortas of
Cx402/2 mice than in those of WT littermates, and, in the latter
animals, was increased by the candesartan and ramipril treatments.
In WT mice, the 2K1C procedure decreased the levels of the
AT1a receptor to the levels of Cx40
2/2 animals, which were not sig-
nificantly affected by this procedure. The L-NAME treatment did not
alter the expression of the AT1a receptor (see Supplementary
material online, Table S2).
Figure 1 Cx40 and Cx37 increase in the aorta of hypertensive mice. (A) Western blots showed increased Cx40 in renin-dependent and
-independent hypertensive WT mice. (B) Cx37 was also higher in the aortas of hypertensive animals. Treatment with candesartan or ramipril
reduced the expression of Cx37 in the spontaneously hypertensive Cx402/2 mice. (C) Western blots demonstrated that Cx37 levels did not
change in the aortic intima of either 2K1C or L-NAME hypertensive mice, and were lower in Cx402/2 than in WT animals. Treatment with cande-
sartan did not affect Cx37 levels in the endothelium of Cx402/2 mice. (D) Cx37 was less abundant in the SMCs than in the ECs of WT controls,
whereas it increased in the SMCs of Cx402/2 mice. A Cx37 increase occurred in the media of all hypertensive mice. The levels of SMC Cx37
were also altered after candesartan treatment in Cx402/2 mice. Data represent mean þ SEM of four experiments. *P, 0.05, **P, 0.01 vs. the
respective WT animals; 8P, 0.05, 88P, 0.01 vs. WT or Cx402/2 untreated or sham-operated animals. (E) En face immunostaining showed that
Cx40, but not Cx37, was increased between ECs of hypertensive mice. (F) Sections confirmed that Cx40 was solely expressed in ECs, whereas
Cx37 was detectable in ECs and in the SMCs of hypertensive mice. L, lumen; M, media. Bar represents 30 mm.
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3.2 Multiple connexins increase in the
aorta of hypertensive mice
After 4 weeks of hypertension, Cx40 increased in WT mice submitted
to either the 2K1C or L-NAME treatment (Figure 1A), due to a tran-
scriptional up-regulation (see Supplementary material online, Figure
S2A). Immunostaining showed that Cx40 was increased solely
between ECs (Figure 1E and F, left panels). At the same time point,
Cx37 was also increased in the aortas of all WT mice made hyperten-
sive, as well as in hypertensive Cx402/2 mice (Figure 1B and see Sup-
plementary material online, Figure S2B), due to an up-regulation in
SMCs (Figure 1C and D). Accordingly, immunostaining and western
blot revealed no significant change of Cx37 in ECs, except for the
expected2 decrease in Cx402/2 mice (Figure 1C, E and F, right
panels). Treatment with either candesartan or ramipril reduced
Cx37 expression in Cx402/2, but not WT mice (Figure 1B and see
Supplementary material online, Figure S2B). The SMC, but not the
EC, distribution was altered after both the candesartan (Figure 1C
and D) and the ramipril treatments (data not shown). Cx45 was
also increased in the aortic SMCs of all hypertensive mice
(Figure 2A) and was reduced under treatment with either candesartan
or ramipril in Cx402/2 but not WT mice (Figure 2A, left panel, and see
Supplementary material online, Figure S2C).
Cx43 increased only in renin-dependent hypertension (Figure 2B),
due to a transcriptional up-regulation (see Supplementary material
online, Figure S2D) which, as judged by its blockade under candesartan
or ramipril treatment, required activation of the renin–angiotensin
system (RAS) (Figure 2B and see Supplementary material online,
Figure S2D). Immunostaining showed that most of Cx43 was expressed
by aortic SMCs (Figure 2C). Antibodies to Ser262 and Ser368 showed
that these changes did not affect the proportion of phosphorylated
Cx43 (see Supplementary material online, Figure S3). These results
show that chronic hypertension is associated with an up-regulation
of all major aortic Cxs, which are differentially regulated by renin-
dependent and -independent mechanisms.
3.3 Cx43 is increased by AngII
Given that Cx43 was the only Cx which selectively increased in
renin-dependent hypertension, and that AngII is the main RAS
Figure 1 (Continued)
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activator in this form of hypertension,30,31 we investigated the
relationship between these two peptides. By exposing freshly iso-
lated aortas of WT mice to AngII, we observed that within 4 h,
10 nM AngII, a concentration that mimics the physiological levels of
the vasoconstricting peptide,18,32–35 significantly increased the
levels of Cx43. However, the two- to three-fold increase in this
protein which was observed in vivo was only reached with micro-
molar concentrations (Figures 3A and B). Therefore, we selected a
concentration of 2 mM AngII for all other experiments. Western
blots showed that within 2 h, 2 mM AngII increased Cx43 in WT
SMCs (Figure 3C), and the phosphorylation of ERK1/2 (Figure 3D).
This phosphorylation was not increased following the L-NAME treat-
ment (Figure 3E), which also did not alter Cx43 expression
(Figure 2B). In the aortas of Cx402/2 mice, AngII induced a
smaller and delayed increase in Cx43, and prevented
the down-regulation of Cx43 expression which occurred in the
absence of the hormone (Figure 3F). Under this condition, the
levels of Cx43 decreased in the aorta of Cx402/2 mice to reach
control values within 48 h. (Figure 3F), due to rundown of AngII,
which is natively high in these animals.7,8 These results show that
Cx43 is up-regulated in parallel with the ERK pathway, due to
RAS activation.
Figure 2 Cx43 and Cx45 are differently affected by renin-dependent and -independent hypertension. (A) Cx45 increased in all WT mice made
hypertensive, and this increase was blocked in Cx402/2 mice by RAS inhibitors (left panel). Cx45 was specifically increased in the aortic SMCs of
hypertensive mice (right panel). (B) In contrast, Cx43 increased only in aortas of renin-dependent models (Cx402/2 and 2K1C). Data represent
mean þ SEM of four experiments. *P, 0.05, **P, 0.01 vs. the respective WT animals; 8P, 0.05, 88P, 0.01 vs. WT or Cx402/2 untreated or
sham-operated animals. (C) Immunostaining showed Cx43 throughout the media of all aortas. Increased numbers of immunospots were observed
in the media of all Cx402/2 and hypertensive 2K1C WT mice. M, media; L, lumen. Bar represents 30 mm.
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3.4 The AngII-induced regulation is seen
in smaller arteries
Using carotid and mesenteric arteries, which express a Cx pattern
analogous to that of the aorta (Figure 4A), we also observed increased
levels of Cx43 and ERK1/2 phosphorylation in Cx402/2 mice
(Figure 4B). When exposed in vitro to AngII, the two types of WT
vessels featured an increased expression of Cx43 and phosphoryl-
ation of ERK1/2 (Figure 4C), as observed in the aorta (Figure 3C and
D). This change was significantly higher in the small-diameter mesen-
teric arteries than in the larger carotids (Figure 4C). These exper-
iments show that chronic hypertension similarly targets the aorta
and the smallest arteries we could test in mice.
3.5 A7r5 cells represent a convenient
model of aortic SMCs
To further investigate the molecular mechanism of the AngII induction
of Cx43, we searched a cell line that would mimic the main features of
primary SMCs. We found that A7r5 expressed a Cx pattern alike that
of aortic SMCs (Figure 5A, C, D) and responded to physiologically rel-
evant concentrations of AngII with a similar increase in Cx43 and
phosphorylated ERK1/2 (P-ERK1/2) (Figure 5A and B). At a 2 mM con-
centration, which induced in A7r5 cells a two- to three-fold increase
in Cx43 similar to that observed in vivo and in isolated aortas, A7r5
cells also increased the expression of Cx43, but not that of Cx37,
Cx40, and Cx45 (Figure 5C and D) and showed a rapid,
Figure 3 AngII stimulates Cx43 expression in a dose-dependent manner. (A and B) Western blots of WT aortas exposed for 4 h to AngII showed
that the peptide increased the levels of Cx43 and P-ERK1/2, at physiologically nanomolar concentrations, and reproduced the two-fold Cx43 increase
observed in vivo, at concentrations .0.1 mM. (C and D) Exposure of WT aortas to 2 mM AngII increased within 2 h Cx43 (C), and P-ERK1/2 (D). (E)
The levels of the P-ERK1/2 increased in aortas of Cx402/2 and 2K1C mice, but not in those of L-NAME-treated mice. (F) A smaller and delayed effect
was observed with aortas of Cx402/2 mice. In the absence of AngII, the levels of Cx43 decreased in this tissue to reach control values within 48 h.
Data represent mean þ SEM of three experiments. *P, 0.05, **P, 0.01, 8P, 0.05 vs. respective untreated WT or Cx402/2 aortas. §P, 0.05 vs.
untreated Cx402/2 aortas at t ¼ 0 h.
Connexin regulation in hypertensive mice 171
AngII-dependent activation of the ERK pathway (Figure 5E). Thus,
A7r5 cells reproduced the main Cx and signalling changes observed
in native aortas.
3.6 AngII increases Cx43 via activation
of the NF-kB pathway
A7r5 cells exposed to AngII increased the proportion of phosphory-
lated IkBa36,37 (Figure 6A and B), with a time course consistent with
that of the Cx43 changes (Figure 5A). Immunostaining demonstrated
that AngII induced the nuclear translocation of the p65-NF-kB tran-
scription factor (Figure 6C). Candesartan, and the inhibitor of the
ERK1/2 pathway PD98059, prevented the AngII-dependent induction
of Cx43 expression, and ERK1/2 and IkBa phosphorylation
(Figure 6B). These results suggest that AngII up-regulates Cx43 via
the activation of the ERK and NF-kB pathways.
3.7 NF-kB binds to the promoter of the
Cx43 gene and activates its transcription
We found a canonical kB site between 2312 and 2301 bp of the
promoter of the rat Gja1 gene. Therefore, we transfected A7r5
cells with a luciferase cDNA, under control of two fragments of the
rat Cx43 promoter, each containing a kB site. After 4 h in the pres-
ence of 2 mM AngII, we observed an increase in luciferase activity,
whether the reporter gene was driven by the short (258 bp) or
long (699 bp) promoter fragment (Figure 6D). This increase was pre-
vented by mutating the kB site (Figure 6D).
We incubated chromatin from control and AngII-stimulated A7r5
cells with antibodies against either the P65 or P50 form of NF-kB.
Both antibodies immunoprecipitated fragments which, by PCR,
yielded a sequence corresponding to 2433 and 2187 bp (relative
to the transcription initiation site38) of the Cx43 promoter
(Figure 6E). After a 2 h exposure to AngII, the recovery of this frag-
ment increased in the presence, but not in the absence, of antibodies
against NF-kB (Figure 6E). These data document that AngII enhances
the binding of NF-kB to the Gja1 promoter.
4. Discussion
The multiple Cxs which are expressed by vascular ECs and SMCs4,6
have been implicated in the physiological function of arteries,39 and
their adaptation to chronic hypertension.22,40 Still, it is not clear
whether and how all vascular Cxs are similarly affected by all forms
of hypertension.41 Comparing models of renin-dependent5 and
-independent hypertension,5,7,10,18 we now show that all hypertensive
mice featured a thickening of the media, which was associated with
increased levels of Cx40 in the intimal ECs, and of Cx37 and Cx45
in the media SMCs. In contrast, Cx43 was up-regulated in the latter
layer, without obvious changes in its phosphorylation, only under con-
ditions of renin-dependent hypertension. These observations docu-
ment that multiple Cx changes are associated with the remodelling
of the arterial wall which occurs in response to the altered mechanical
and hormonal environment of hypertension. They further show that
although the control of Cx37, Cx40, and Cx45 expression does not
depend on the circulating levels of renin and AngII, these hormones
are required for the control of Cx43. Given that AngII ultimately med-
iates the vasoconstriction and SMC changes42 that result from RAS
activation,31 we have investigated the effects of this peptide. Consist-
ent with previous data in rats and cultured SMCs,42 we have found
Figure 4 Carotid and mesenteric arteries show a Cx pattern and
responsiveness to AngII similar to those of aorta. (A, left panels)
Immunostaining showed punctate Cx43 throughout the carotid
media. Increased numbers of immunospots were observed in the
media of Cx402/2 mice. (A, right panels) Cx37 was detectable in
the media of hypertensive but not control mice. L, lumen; M,
media. Bar represents 10 mm. (B) Western blots showed that
Cx37, Cx43, and P-ERK1/2 were increased in carotid and mesenteric
arteries of Cx402/2 mice. (C ) After a 4 h exposure of WT carotids
and mesenteric arteries to 2 mM AngII, Cx43 and P-ERK1/2, but not
Cx37, were increased. Data represent mean þ SEM of three exper-
iments. *P, 0.05, **P, 0.01 vs. respective untreated vessels or
WT animals.
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that within a few hours, physiologically relevant levels of AngII
increased the expression of Cx43, but not of Cx37, Cx40, and
Cx45. This change is induced by the activation of ERK1/2 which, by
causing the phosphorylation of IkBa,43,44 results in the nuclear trans-
location of NF-kB. We now document that NF-kB directly and
specifically binds in situ to the promoter of the Gja1 gene which
codes for Cx43, and that the NF-kB binding is enhanced by AngII.
The Cx43 changes are rapidly induced by the ERK1/2 activation,
but persist even after the ERK activity has returned to basal levels,
indicating that other mechanisms contribute to the sustained
elevation of Cx43 expression.
These experiments provide the first coherent explanation of how a
renin increase enhances Cx43: (i) the activation of RAS increases the cir-
culating levels of AngII; (ii) elevated AngII results in peripheral vasocon-
striction, causing hypertension, and triggering SMC hypertrophy and
proliferation; (iii) in parallel, AngII promotes, via phosphorylation of
ERK1/2, the binding of NF-kB to the Gja1 promoter; (iv) this binding
trans-activates the Gja1 gene, leading to increased production of
Cx43 in the SMCs (see Supplementary material online, Figure S4). The
finding of comparable Cx43 changes in the aorta, the carotids, and
the small mesenteric arteries suggests that our observations apply to
the many vascular compartments targeted by hypertension.15,45
Figure 5 A7r5 cells feature the same Cx43 and signalling changes observed in aortic SMCs. (A and B) Western blots of A7r5 cells exposed for 2 h
to increasing concentrations of AngII showed that the peptide increased the levels of Cx43 and P-ERK1/2 at concentrations similar to those that
elicited comparable changes in aortic SMCs. (C and D) Western blots showed that A7r5 cells expressed Cx43, Cx37, Cx40, and Cx45. Two-
micromolar AngII increased Cx43, but not Cx37, Cx40, and Cx45. (E) AngII also increased the levels of P-ERK1/2. Results are means þ SEM of
three experiments. *P, 0.05, **P, 0.01 vs. untreated cells.
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Figure 6 The AngII-induced increase in Cx43 requires the activation of ERK and NF-kB pathways. (A) Within 2 h, AngII increased the phosphoryl-
ation of IkBa in A7r5 cells. Results are means þ SEM of three experiments. **P, 0.01 vs. untreated cells. (B) Within 2 h, AngII also increased Cx43,
P-ERK1/2, and P-IkBa levels. Both candesartan and PD98059 prevented these effects. (C) After 4 h, 2 mM AngII induced a translocation of the P65
phosphorylated form of NF-kB into the nucleus of A7r5 cells. Bar, 20 mm. (D) AngII increased luciferase activity of A7r5 cells transfected with either a
short or long Gja1 promoter fragment. Mutation of the NF-kB motif in either one of the two promoter fragments prevented the increased in the
luciferase activity observed after AngII stimulation. (E) Quantitative RT–PCR showed that AngII increased the amount of the Gja1 promoter fragment,
recovered using antibodies against either the P65 or the P50 forms of NF-kB. Results are means þ SEM of three experiments. **P, 0.01,
***P, 0.001 vs. untreated cells; 88P, 0.01, 888P, 0.001 vs. AngII-treated cells.
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Our data further implicate that other mechanisms, possibly dependent
on the mechanical forces that impinge on the arterial walls during hyper-
tension,1,46,47 in the control of Cx37, Cx40, and Cx45, as well as in the
sustained elevation of Cx43, once the activation of ERK1/2 ends.
The significance of the increase in Cx43 in renin-dependent hyper-
tension remains to be elucidated. Beside its major vasoconstrictor
effect, AngII also stimulates vascular remodelling by promoting SMC
growth and the production of extra cellular matrix, which contribute
to increased aortic stiffness,48 a frequent consequence of hyperten-
sion.49 Increased Cx43 expression in the presence of elevated AngII
may therefore contribute to regulate the elasticity of the vascular
wall. If so, the pharmacological targeting of Cx43 may be therapeuti-
cally useful, in addition to the standard anti-hypertensive drugs which
aim at counteracting the AngII effects.50
In summary, by comparing control and Cx40-lacking mice, under
conditions of renin-dependent (2K1C) and renin-independent hyper-
tension (L-NAME administration), we have found that Cx37, Cx40,
and Cx45 are up-regulated in the wall of different types of arteries,
probably as a result of the increased mechanical forces impinging on
the vessels’ wall. In contrast, Cx43 was up-regulated only in the renin-
dependent model of hypertension, due to an AngII-dependent mech-
anism, which specifically activates the transcription of the Cx43 gene.
These findings document that the expression of several vascular con-
nexins is affected by chronic hypertension, though by different mech-
anisms, and in different compartments of the arterial wall.
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